MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5

Carcinogenesis

Volumn 36, Issue 12, 2015, Pages 1484-1493

  Li, Pei Long ^a   Zhang, Xin ^a   Wang, Li Li ^a   Du, Lu Tao ^a   Yang, Yong Mei ^a   Li, Juan ^a   Wang, Chuan Xin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; BIRC5 PROTEIN, HUMAN; FLUOROURACIL; INHIBITOR OF APOPTOSIS PROTEIN; MICRORNA; MIRN218 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; BINDING SITE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN REGULATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROGNOSIS; RNA INTERFERENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BASE SEQUENCE; BINDING SITES; BIOMARKERS, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RNA INTERFERENCE;

EID: 84949801975     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv145     Document Type: Article

References (46)

1. Zhao, P. et al. (2010) Cancer trends in China. Jpn. J. Clin. Oncol., 40, 281-285.
2. Alberts, S.R. et al. (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J. Clin. Oncol., 23, 9243-9249.
3. Andre, T. et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med., 350, 2343-2351.
4. Meyerhardt, J.A. et al. (2005) Systemic therapy for colorectal cancer. N. Engl. J. Med., 352, 476-487.
5. Hector, S. et al. (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother. Pharmacol., 48, 398-406.
6. Ahmad, S. (2010) Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem. Biodivers., 7, 543-566.
7. Landriscina, M. et al. (2009) Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid. Redox Signal., 11, 2701-2716.
8. Sau, A. et al. (2010) Glutathione transferases and development of new principles to overcome drug resistance. Arch. Biochem. Biophys., 500, 116-122.
9. Zhou, Y. et al. (2014) miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol. Oncol., 8, 83-92.
10. Karaayvaz, M. et al. (2013) miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis., 4, e659.
11. Chan, J.K. et al. (2014) The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol. Oncol., 132, 739-744.
12. Bernstein, E. et al. (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 409, 363-366.
13. Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-233.
14. Zhang, L. et al. (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA, 103, 9136-9141.
15. Calin, G.A. et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA, 101, 2999-3004.
16. Yu, F. et al. (2010) Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene, 29, 4194-4204.
17. Li, J. et al. (2009) MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res., 15, 3998-4008.
18. Li, J. et al. (2011) miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett., 304, 52-59.
19. He, X. et al. (2012) MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol. Med., 18, 1491-1498.
20. Tu, Y. et al. (2013) MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res., 73, 6046-6055.
21. Gao, X. et al. (2014) The emerging role of tumor-suppressive micro-RNA-218 in targeting glioblastoma stemness. Cancer Lett., 353, 25-31.
22. Wu, D.W. et al. (2014) Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by micro-RNA-218 targeting. Carcinogenesis, 35, 1823-1829.
23. Ambrosini, G. et al. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3, 917-921.
24. Alajez, N.M. et al. (2011) MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res., 71, 2381-2391.
25. Gao, C. et al. (2010) Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer, 116, 41-49.
26. Wu, D.W. et al. (2010) Paxillin predicts survival and relapse in nonsmall cell lung cancer by microRNA-218 targeting. Cancer Res., 70, 10392-10401.
27. Peng, S.C. et al. (2014) MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma. PLoS One, 9, e102403.
28. Zhu, Z. et al. (2014) Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival. J. Surg. Oncol., 109, 89-94.
29. Xin, S.Y. et al. (2014) Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J. Gastroenterol., 20, 6906-6911.
30. Dickinson, R.E. et al. (2004) Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br. J. Cancer, 91, 2071-2078.
31. Shivapurkar, N. et al. (2001) Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum. Pathol., 32, 169-177.
32. Dallol, A. et al. (2003) SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res., 63, 1054-1058.
33. Kinoshita, T. et al. (2012) Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget, 3, 1386-1400.
34. Uesugi, A. et al. (2011) The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res., 71, 5765-5778.
35. Ye, Q. et al. (2014) ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene, 33, 1828-1839.
36. Kanwar, J.R. et al. (2011) Targeting survivin in cancer: the cell-signalling perspective. Drug Discov. Today, 16, 485-494.
37. Yamanaka, K. et al. (2011) YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int. J. Oncol., 39, 569-575.
38. Okamoto, K. et al. (2010) Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res., 70, 10402-10410.
39. Lu, C.D. et al. (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res., 58, 1808-1812.
40. Adida, C. et al. (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet, 351, 882-883.
41. Gottesman, M.M. et al. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2, 48-58.
42. Zaffaroni, N. et al. (2002) Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Updat., 5, 65-72.
43. Wang, T. et al. (2009) Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int. J. Cancer, 125, 1921-1925.
44. Qu, L. et al. (2014) Inhibitory effect of biosynthetic nanoscale peptide Melittin on hepatocellular carcinoma, driven by survivin promoter. J. Biomed. Nanotechnol., 10, 695-706.
45. Danenberg, P.V. (1977) Thymidylate synthetase -a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta, 473, 73-92.
46. Chu, E. et al. (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother. Pharmacol., 52, S80-89